Printer Friendly

DEPRENYL RESEARCH LIMITED REASSURES SHAREHOLDERS

 DEPRENYL RESEARCH LIMITED REASSURES SHAREHOLDERS
 TORONTO, Aug. 27 /PRNewswire/ -- Deprenyl Research Limited


(NASDAQ: DEPLF; TSE: DEP) has been following the recent pressure on its share price. The company today announced it sees no significant change and does not anticipate any changes in the continuing positive trends of its operation.
 An interim review of the third quarter performance indicates an unchanging pattern of year-over-year increases in pharmaceutical sales. The company's estimate for the third quarter at this time is net income from pharmaceutical operations of about $1 million versus $728,000 for the same period last year, and earnings per share of 11 cents versus 9 cents for the same quarter last year. Investment activities have so far been extremely successful in the third quarter and will add significantly to the company's earnings. Development of the company's pipeline of drugs is proceeding on schedule and within budget. The company remains profitable, debt free, and maintains its cash assets.
 Deprenyl Research Limited is a Canadian pharmaceutical company specializing in products for neurologic diseases, other chronic conditions and dermatology.
 -0- 8/27/92
 /CONTACT: Martin Barkin, M.D., president of Deprenyl Research, 416-537-4372, or fax, 416-537-1653; or Irving L. Straus of Straus Corporate Communications, 212-768-2477, or fax, 212-768-2476, for Deprenyl Research/
 (DEPLF) CO: Deprenyl Research Limited ST: Ontario IN: MTC SU:


GK-TS -- NY047 -- 3962 08/27/92 13:08 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 27, 1992
Words:227
Previous Article:PHILADELPHIA FED RELEASES THIRD QUARTER 1992 SURVEY OF PROFESSIONAL FORECASTERS
Next Article:MHI GROUP NAMES J.C. OGIER MATHEWES VP, CFO
Topics:


Related Articles
DEPRENYL RESEARCH CO-CHAIRMAN SENDS LETTER TO SHAREHOLDERS
DEPRENYL RESEARCH CHAIRMAN ISSUES STATEMENT ON SELL ADVISORY
DEPRENYL RESEARCH ELECTS MARTIN BARKIN PRESIDENT, CHIEF OPERATING OFFICER AND DIRECTOR
DEPRENYL RESEARCH NOTES NO CHANGE IN COMPANY TO ACCOUNT FOR CURRENT PRESSURES ON SHARE PRICE
DEPRENYL ANNOUNCES AGREEMENT TO ACQUIRE CONTROL OF LIPOPHARM
DEPRENYL ACQUIRES CONTROL OF QUEBEC-BASED LIPOPHARM INC.
DEPRENYL RESEARCH ANNOUNCES FINAL PROSPECTUS OF BONE HEALTH INC.
DEPRENYL RESEARCH LTD. & BONE HEALTH INC. TO AWAIT FULL ANALYSIS OF CLINICAL TRIALS BEFORE ISSUING FINAL AMENDMENTS TO PROSPECTUS
MARTIN BARKIN NAMED CEO OF DEPRENYL RESEARCH LIMITED MORTON SHULMAN TO REMAIN CO-CHAIRMAN
DEPRENYL RESEARCH REPORTS EARNINGS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters